VALUTAZIONE DEI RECETTORI PER LHRH NEL TESSUTO DI LEIOMIOMA, MIOMETRIO ED ENDOMETRIO UMANO

Translated title of the contribution: LHRH receptors in human uterine leiomyomata, myometrium, and endometrial tissue

M. Marinaccio, S. Reshkin, V. Pinto, A. Paradiso

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Uterine leiomyoma is the most common female benign pelvic tumor, affecting 20-25% of women during their reproductive years. There is strong clinical evidence that these tumors are estrogen-dependent for their growth, as also supported by their clear regression after the menopause. Although large clinical trials have not yet been reported, according to the estrogen dependency of uterine fibroids, LHRH agonists have been shown to be effective in the treatment of these conditions because they produce a condition of temporary hypoestrogenism secondary to the specific hypogonadotrophinism. This study was designed to evaluate if specific binding sites for LHRH are present in human uterine leiomyomata, myometrium and endometrial tissue. These tissues were taken from the fresh operative specimens of 14 patients who had undergone total hysterectomy for uterine leiomyomata. The results of this study demonstrate the presence of a LHRH specific binding site in uterine leiomyomata in 26% of cases; this specific binding site is also present both in myometrium and in endometrial tissue in 71% of cases. Moreover our study shows, for the first time, the high specificity of binding between LHRH agonist (Goserelin) and natural LHRH receptor. In accordance with our results, a direct effect of LHRH agonists on fibroid tissue can be stressed.

Original languageItalian
Pages (from-to)519-526
Number of pages8
JournalMinerva Ginecologica
Volume46
Issue number10
Publication statusPublished - 1994

Fingerprint

LHRH Receptors
Myometrium
Leiomyoma
Gonadotropin-Releasing Hormone
Binding Sites
Estrogens
Goserelin
Menopause
Hysterectomy
Neoplasms
Clinical Trials
Growth

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

VALUTAZIONE DEI RECETTORI PER LHRH NEL TESSUTO DI LEIOMIOMA, MIOMETRIO ED ENDOMETRIO UMANO. / Marinaccio, M.; Reshkin, S.; Pinto, V.; Paradiso, A.

In: Minerva Ginecologica, Vol. 46, No. 10, 1994, p. 519-526.

Research output: Contribution to journalArticle

Marinaccio, M. ; Reshkin, S. ; Pinto, V. ; Paradiso, A. / VALUTAZIONE DEI RECETTORI PER LHRH NEL TESSUTO DI LEIOMIOMA, MIOMETRIO ED ENDOMETRIO UMANO. In: Minerva Ginecologica. 1994 ; Vol. 46, No. 10. pp. 519-526.
@article{40d08d9437e44fcf89d4c7fefb805eca,
title = "VALUTAZIONE DEI RECETTORI PER LHRH NEL TESSUTO DI LEIOMIOMA, MIOMETRIO ED ENDOMETRIO UMANO",
abstract = "Uterine leiomyoma is the most common female benign pelvic tumor, affecting 20-25{\%} of women during their reproductive years. There is strong clinical evidence that these tumors are estrogen-dependent for their growth, as also supported by their clear regression after the menopause. Although large clinical trials have not yet been reported, according to the estrogen dependency of uterine fibroids, LHRH agonists have been shown to be effective in the treatment of these conditions because they produce a condition of temporary hypoestrogenism secondary to the specific hypogonadotrophinism. This study was designed to evaluate if specific binding sites for LHRH are present in human uterine leiomyomata, myometrium and endometrial tissue. These tissues were taken from the fresh operative specimens of 14 patients who had undergone total hysterectomy for uterine leiomyomata. The results of this study demonstrate the presence of a LHRH specific binding site in uterine leiomyomata in 26{\%} of cases; this specific binding site is also present both in myometrium and in endometrial tissue in 71{\%} of cases. Moreover our study shows, for the first time, the high specificity of binding between LHRH agonist (Goserelin) and natural LHRH receptor. In accordance with our results, a direct effect of LHRH agonists on fibroid tissue can be stressed.",
keywords = "LHRH receptors, LHRH-agonists, Uterine leiomyomata",
author = "M. Marinaccio and S. Reshkin and V. Pinto and A. Paradiso",
year = "1994",
language = "Italian",
volume = "46",
pages = "519--526",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "10",

}

TY - JOUR

T1 - VALUTAZIONE DEI RECETTORI PER LHRH NEL TESSUTO DI LEIOMIOMA, MIOMETRIO ED ENDOMETRIO UMANO

AU - Marinaccio, M.

AU - Reshkin, S.

AU - Pinto, V.

AU - Paradiso, A.

PY - 1994

Y1 - 1994

N2 - Uterine leiomyoma is the most common female benign pelvic tumor, affecting 20-25% of women during their reproductive years. There is strong clinical evidence that these tumors are estrogen-dependent for their growth, as also supported by their clear regression after the menopause. Although large clinical trials have not yet been reported, according to the estrogen dependency of uterine fibroids, LHRH agonists have been shown to be effective in the treatment of these conditions because they produce a condition of temporary hypoestrogenism secondary to the specific hypogonadotrophinism. This study was designed to evaluate if specific binding sites for LHRH are present in human uterine leiomyomata, myometrium and endometrial tissue. These tissues were taken from the fresh operative specimens of 14 patients who had undergone total hysterectomy for uterine leiomyomata. The results of this study demonstrate the presence of a LHRH specific binding site in uterine leiomyomata in 26% of cases; this specific binding site is also present both in myometrium and in endometrial tissue in 71% of cases. Moreover our study shows, for the first time, the high specificity of binding between LHRH agonist (Goserelin) and natural LHRH receptor. In accordance with our results, a direct effect of LHRH agonists on fibroid tissue can be stressed.

AB - Uterine leiomyoma is the most common female benign pelvic tumor, affecting 20-25% of women during their reproductive years. There is strong clinical evidence that these tumors are estrogen-dependent for their growth, as also supported by their clear regression after the menopause. Although large clinical trials have not yet been reported, according to the estrogen dependency of uterine fibroids, LHRH agonists have been shown to be effective in the treatment of these conditions because they produce a condition of temporary hypoestrogenism secondary to the specific hypogonadotrophinism. This study was designed to evaluate if specific binding sites for LHRH are present in human uterine leiomyomata, myometrium and endometrial tissue. These tissues were taken from the fresh operative specimens of 14 patients who had undergone total hysterectomy for uterine leiomyomata. The results of this study demonstrate the presence of a LHRH specific binding site in uterine leiomyomata in 26% of cases; this specific binding site is also present both in myometrium and in endometrial tissue in 71% of cases. Moreover our study shows, for the first time, the high specificity of binding between LHRH agonist (Goserelin) and natural LHRH receptor. In accordance with our results, a direct effect of LHRH agonists on fibroid tissue can be stressed.

KW - LHRH receptors

KW - LHRH-agonists

KW - Uterine leiomyomata

UR - http://www.scopus.com/inward/record.url?scp=0027962484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027962484&partnerID=8YFLogxK

M3 - Articolo

VL - 46

SP - 519

EP - 526

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 10

ER -